F
Francisco Sanchez-Vega
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 115
Citations - 20975
Francisco Sanchez-Vega is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 84 publications receiving 13474 citations. Previous affiliations of Francisco Sanchez-Vega include Washington University in St. Louis & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Intraoperative opioids are associated with decreased recurrence rates in colon adenocarcinoma: a retrospective observational cohort study.
Jonathan B. Yuval,Jasme Lee,Fan Wu,Hannah Thompson,Floris S Verheij,Hersh Gupta,Takeshi Irie,Joseph R. Scarpa,Patrick J. McCormick,J. R. Smith,Jinru Shia,Martin R. Weiser,Francisco Sanchez-Vega,Kay See Tan,Gregory W. Fischer,Julio Garcia-Aguilar,Joshua S. Mincer +16 more
TL;DR: In this paper , the authors evaluated the relationship between intraoperative opioid exposure, DNA mismatch repair deficient (dMMR) subtype, and oncological outcomes after surgery for colon adenocarcinoma.
Journal ArticleDOI
Molecular determinants of response and resistance to anti-PD-(L)1 blockade in patients with NSCLC profiled with targeted next-generation sequencing (NGS).
Matthew D. Hellmann,Francisco Sanchez-Vega,Konnor La,Hira Rizvi,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Walid K. Chatila,Philip Jonsson,Kathryn C. Arbour,Jamie E. Chaft,Charles M. Rudin,Mark G. Kris,Michael F. Berger,Barry S. Taylor,Ahmet Zehir,Maria E. Arcila,Marc Ladanyi,Gregory J. Riely,Nikolaus Schultz +19 more
TL;DR: Anti-PD-(L)1 therapy has revolutionized treatment for patients with NSCLC and non-synonymous tumor mutation burden by whole exome sequencingAssessment of TMB in patients treated with anti-PD-L1 therapy shows positive results.
Journal ArticleDOI
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways.
Smita Sihag,Samuel C Nussenzweig,Henry Walch,Meier Hsu,Kay See Tan,Francisco Sanchez-Vega,Walid K. Chatila,Sergio De La Torre,Assem Patel,Yelena Y. Janjigian,Steven Brad Maron,Geoffrey Y. Ku,Laura H. Tang,Jaclyn F. Hechtman,Pari Shah,Abraham J. Wu,David R. Jones,Daniela Molena,David B. Solit,Nikolaus Schultz,Michael F. Berger +20 more
TL;DR: In this paper, a large cohort of patients with lower esophageal and junctional adenocarcinoma, prospectively sequenced by MSK-IMPACT with high-quality clinical annotation, were subdivided according to treatment intent, curative vs. palliative, which closely mirrored clinical staging.
Journal ArticleDOI
Genomic mapping of metastatic organotropism in lung adenocarcinoma.
Harry B. Lengel,Brooke Mastrogiacomo,J.G. Connolly,Kay See Tan,Yuan Liu,Cameron Fick,Di He,Manendra Babu Lankadasari,Baby A. Satravada,Yichao Sun,Ritika Kundra,Chris Fong,Shaleigh Smith,Gregory J. Riely,Charles M. Rudin,Daniel R. Gomez,David B. Solit,Michael F. Berger,Bo Li,Marty W. Mayo,Irina Matei,David Lyden,Prasad S. Adusumilli,Nikolaus Schultz,Francisco Sanchez-Vega,David R. Jones +25 more
TL;DR: In this paper , the authors analyzed 2,532 lung adenocarcinomas (LUAD) to identify the clinicopathological and genomic features associated with metastasis, metastatic burden, organotropism, and metastasis-free survival.
Journal ArticleDOI
Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma
Raul Caso,James G. Connolly,Jian Zhou,Jian Zhou,Kay See Tan,James J. Choi,Gregory D. Jones,Brooke Mastrogiacomo,Francisco Sanchez-Vega,Bastien Nguyen,Gaetano Rocco,Daniela Molena,Smita Sihag,Prasad S. Adusumilli,Matthew J. Bott,David R. Jones +15 more
TL;DR: In this article, a multivariable logistic regression model that considered preoperative clinical and genomic variables was constructed to determine pathologic lung adenocarcinoma (LUAD) metastasis prior to surgery.